Ontology | ID | Description | GeneRatio | BgRatio | pvalue | p.adjust | qvalue |
---|---|---|---|---|---|---|---|
BP | GO:0038066 | p38MAPK cascade | 3/10 | 53/18670 | 2.56e−06 | 5.28e−04 | 2.04e−04 |
BP | GO:0043312 | Neutrophil degranulation | 5/10 | 485/18670 | 2.62e−06 | 5.28e−04 | 2.04e−04 |
BP | GO:0002283 | Neutrophil activation involved in immune response | 5/10 | 488/18670 | 2.70e−06 | 5.28e−04 | 2.04e−04 |
BP | GO:0042119 | Neutrophil activation | 5/10 | 498/18670 | 2.99e−06 | 5.28e−04 | 2.04e−04 |
BP | GO:0002446 | Neutrophil mediated immunity | 5/10 | 499/18670 | 3.02e−06 | 5.28e−04 | 2.04e−04 |
CC | GO:0034774 | Secretory granule lumen | 5/10 | 321/19717 | 2.61e−07 | 6.17e−06 | 4.57e−06 |
CC | GO:0060205 | Cytoplasmic vesicle lumen | 5/10 | 338/19717 | 3.38e−07 | 6.17e−06 | 4.57e−06 |
CC | GO:0031983 | Vesicle lumen | 5/10 | 339/19717 | 3.43e−07 | 6.17e−06 | 4.57e−06 |
CC | GO:0035580 | Specific granule lumen | 3/10 | 62/19717 | 3.50e−06 | 4.72e−05 | 3.50e−05 |
CC | GO:0042581 | Specific granule | 3/10 | 160/19717 | 6.04e−05 | 6.52e−04 | 4.83e−04 |
MF | GO:0004252 | Serine-type endopeptidase activity | 2/10 | 160/17697 | 0.003 | 0.077 | 0.042 |
MF | GO:0008236 | Serine-type peptidase activity | 2/10 | 182/17697 | 0.004 | 0.077 | 0.042 |
MF | GO:0017171 | Serine hydrolase activity | 2/10 | 186/17697 | 0.005 | 0.077 | 0.042 |
MF | GO:0016813 | Hydrolase activity, acting on carbon–nitrogen (but not peptide) bonds, in linear amidines | 1/10 | 11/17697 | 0.006 | 0.077 | 0.042 |
MF | GO:0004707 | MAP kinase activity | 1/10 | 14/17697 | 0.008 | 0.077 | 0.042 |
KEGG | hsa01230 | Biosynthesis of amino acids | 3/8 | 75/8076 | 4.17e−05 | 0.004 | 0.003 |
KEGG | hsa05169 | Epstein–Barr virus infection | 3/8 | 202/8076 | 7.87e−04 | 0.025 | 0.020 |
KEGG | hsa05205 | Proteoglycans in cancer | 3/8 | 205/8076 | 8.21e−04 | 0.025 | 0.020 |
KEGG | hsa00010 | Glycolysis/gluconeogenesis | 2/8 | 67/8076 | 0.002 | 0.030 | 0.024 |
KEGG | hsa05218 | Melanoma | 2/8 | 72/8076 | 0.002 | 0.030 | 0.024 |